TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cumulative Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion With PSA Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: vasopressor dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of women with PUL waived from laparoscopic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cognitive abilities evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep phenotype characterization
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incomplete surgical excision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Percent Predicted Forced Vital Capacity (%FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Device posts Sensor Off within 1 minute after sensor removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of chest retractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of nasal bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of vomit episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of conversion to Alzheimer's Disease (AD)
Endpoint domain: Mortality/survival
Primary endpoint: Airway constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total daily insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Daily Cigarette Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of E-cigarettes Used Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of PSMA ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cognitive performance evaluation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evaluation of Depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in guideline congruence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early miscarriage loss
Endpoint domain: Mortality/survival
Primary endpoint: Blood flow of the ophthalmic artery (ml/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First-phase secretion Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Second-phase secretion Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: First-phase secretion C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Second-phase secretion C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacokinetics of naftopidil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of sperm in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence and severity of distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cognitive Status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of Patient Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Performance in clinical colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of post-operative atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent reduction in partial seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Paired Difference of Skeletal Age Estimate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium x phosphorus change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CPET score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of tele-notifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of infusion reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Personal Recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline on Maintenance of Wakefulness Test (MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological response to HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity and safety of TA-HPV
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving Antibody Titers ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic yield of pathogenic and likely pathogenic genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of unplanned hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ACR five point rating scale for mammography images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR five point rating scale for echography images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR five point rating scale for MRI imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug use levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area sensitized with histamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: oral bacterial colonization status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment admission by three months following parole
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment retention by three months following parole
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recidivism at nine months following parole
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Physical Activity Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of Appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wound Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Whole-mouth Mean Modified Gingival Index (Mean MGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-mouth Mean Plaque Index (Mean PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CYP3A4*1G Polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Stiffness Index (SSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of non-invasive pregnancy test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Neonatal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum levels of C terminal segment of fibroblast growth factor 23 (FGF23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of Urolithiasis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Premenstrual Tension Scale (PMTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inventory of Depression Symptoms (IDS-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Michelson SSRI Withdrawal Checklist
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events grade >3
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Knowledge Survey score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in masseter pain by visual analog pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in masseter pain by pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intimate partner violence with main partner
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of wife beating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Actions to support victims of gender-based violence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: One-year Incidence of Chlamydial and Gonococcal Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of ethanol responders vs. non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of SICI in responding vs. non-responding ET patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HIV viral load increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of abdominal aortic aneurysm treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End-of-treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Final tuberculosis treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adverse events of interest
Endpoint domain: Adverse events/effects
Primary endpoint: Mean maximum plasma concentration (Cmax) of E2609
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under plasma concentration versus time curve from time zero to time of last quantifiable concentration (AUC(0-t)) of E2609
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under plasma concentration versus time curve from time zero to infinity (AUC(0-inf)) of E2609
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocc AEs
Endpoint domain: Adverse events/effects
Primary endpoint: npat AEs
Endpoint domain: Adverse events/effects
Primary endpoint: nocc SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: npat SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: nocc AESI
Endpoint domain: Adverse events/effects
Primary endpoint: npat AESI
Endpoint domain: Adverse events/effects
Primary endpoint: npat Safety X-rays
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants positive for pre labor rupture of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Health Questionnaire mood subscale (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Infants Who Undergo in Hospital PDA Ligations or Who Have an Open Ductus at the Time of Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of false positive findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of longitudinal dysfunction of left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effect of myocarditis damage due to myocardial fibrosis on longitudinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Patient's Assessment of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Without Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Area under the concentration-time curve from time zero (pre-dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areal Bone Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Valve Events Rate Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamic Performance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New York Heart Association Improvement Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: livebirths (>37 weeks of gestation)
Endpoint domain: Mortality/survival
Primary endpoint: premature livebirths (> 24, but <37 weeks of gestation)
Endpoint domain: Mortality/survival
Primary endpoint: Secondary brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pain score during introduction of catheter and during the injection of dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficiency of the new technique in filling the uterine cavity with the dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Moderate or Greater Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Moderate or Greater and/or Vaccine-related Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Vaccine Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Substance Use Consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Violent Charges
Endpoint domain: Adverse events/effects
Primary endpoint: Change in kidney fibrosis assessed by DW-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in kidney fibrosis assessed by urinary markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quick-DASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pregnancy rate per embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Peak LDL particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tear Osmolarity Threshold > 308 mOsm/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer Test Threshold < 7 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Film Breakup Time Threshold < 5 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reaction Time (RTI) Milliseconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotional Recognition Task (ERT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mood and Motivation Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum Bactericidal Assay (rSBA) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Radiographical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on visual analog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JTX-4014
Endpoint domain: Adverse events/effects
Primary endpoint: Performance in the implicat task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance in the Similitude task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Creatine Rephosphorylation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in the KUJALA scoring questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BP variability level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resection rate (R0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of drug resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the proportion of CRT responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Short Moods and Feelings Questionnaire (SMFQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of use of essential oils
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual Acuity of the Amblyopic Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CD146s levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteinuria dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Preference for goal of care regarding medical interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin Abscess Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: One year overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction rate of ET-sevo in achieving BIS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD signal in fMRI of brain areas associated with emotional memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD signal in fMRI of brain areas associated with working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Extent of extraction of nalbuphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Per Cent Change of Forced Vital Capacity (FVC) After Bronchodilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fibromyalgia impact questionnaire-FIQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Patients With Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Hemostasis at 4 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCG quantification in challenge site biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Amplitudes of early visually evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Latencies of early visually evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative risk of developing melanoma
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative DIT increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic status at 6 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iron status at 6 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intimal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Non-invasive detection of skin tumor margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average dyspnea over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian rhythm of Erythropoietin and Melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absorption and metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patients without endovascular therapy obtained >50% reperfusion at 4-6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes